News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chimerix, Inc. (CMRX)'s Brincidofovir Selected For Two Oral Presentations Highlighting Resistance Data In CMV And Adenovirus At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC)


9/3/2014 7:53:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that new data on its investigational broad-spectrum antiviral brincidofovir (BCV, CMX001) will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being held September 5-9, 2014 at the Walter E. Washington Convention Center in Washington, DC.

Two oral presentations will review new in vitro and in vivo studies that advance the understanding of brincidofovir's resistance profile specific for two important viral pathogens: cytomegalovirus (CMV) and adenovirus (AdV):

Combination Activity and Emerging Resistance Profile of Brincidofovir in CMV Prevention and Treatment

  • Date: Sunday, September 7 at 9:45 a.m. EDT
  • Session: Hepatitis and CMV: New and Noteworthy (Presentation V-677)
  • Location: Room 150B

Resistance Profile of Adenovirus Exposed to Brincidofovir In Vitro and In Vivo

  • Date: Monday, September 8 at 9:45 a.m. EDT
  • Session: Respiratory Viruses: Treatment Challenges and Viral Kinetics (Presentation V-1302)
  • Location: Salon C

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (BCV, CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, the Phase 3 study of brincidofovir for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant recipients. In addition, Chimerix is enrolling the pilot portion of the Phase 3 AdVise study of brincidofovir for treatment of adenovirus infection. Chimerix is also working with BARDA to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications ir@chimerix.com 919-287-4125

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES